Organization
Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China
11 abstracts
Abstract
The safety of atezolizumab plus bevacizumab (atezo/bev) treatment in Chinese patients (pts) with hepatocellular carcinoma (HCC) with active hepatitis B virus (HBV) infection: Results from the TALENTop study.Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Department of Hepatobiliary Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou, China, Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China,
Abstract
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.Org: Fujian Cancer Hospital, First Chest Radiotherapy Department, Hunan Cancer Hospital, Changsha, China, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Department of Melanoma Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China, The Third People's Hospital of Zhengzhou,
Abstract
Neoadjuvant immunotherapy (PD-1) combined with chemotherapy for locally advanced thoracic esophageal carcinoma (EC): A single-arm, open-label, phase II study.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,
Abstract
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.Org: Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China, Women's Hospital School of Medicine Zhejiang University,
Abstract
Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Department II of breast, Linyi Cancer Hospital,
Abstract
Patient-controlled subcutaneous analgesia with hydromorphone versus oral oxycodone for opioid titration of cancer pain: A prospective multicenter randomized trial.Org: Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China, Tongji Hospital of Tongji Medical College,
Abstract
ANTICIPATE phase I: Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).Org: Fudan University Shanghai Cancer Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, The Second Hospital of Tianjin Medical University (China), Carolina Urologic Research Center, Asieris Pharmaceuticals Co., Ltd,
Abstract
Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tongji Medical College Huazhong University of Science and Technology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, College of Biomedicine and Health,
Abstract
Gut microbiota profiling and clinical response in patients with metastatic non-small cell lung cancer receiving endothelial growth factor-tyrosine kinase inhibitors (EGFR-TKI).Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital,
Abstract
A novel prognostic model for high-grade endometrial cancer using combined neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR).Org: Qilu Hospital of Shandong University, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Women's Hospital,
Abstract
A FAMILIAL RISK SURVEY OF ANKYLOSING SPONDYLITIS IN CHINESE HAN POPULATION Org: 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Jishuitan Hospital, Beijing, Affiliated Hospital of Zhengzhou Unniversity, Affiliated Hospital of Zhengzhou University, Zhengzhou, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China,